Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
20
JAGX Quote, Financials, Valuation and Earnings
Last price:
$1.11
Seasonality move
:
107.52%
Day range:
$1.07 - $1.13
52-week range:
$1.00 - $33.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.39x
P/B ratio:
0.45x
Volume:
52.2K
Avg. volume:
300.7K
1-year change:
-95.61%
Market cap:
$1.4M
Revenue:
$11.7M
EPS (TTM):
-$33.98
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
JAGX
Jaguar Health, Inc.
|
$3.7M | -$5.08 | 20.18% | -92.94% | $25.50 |
|
ABT
Abbott Laboratories
|
$11.4B | $1.30 | 7.51% | -71.7% | $144.43 |
|
GOVX
GeoVax Labs, Inc.
|
-- | -- | -100% | -- | $9.63 |
|
MRK
Merck & Co., Inc.
|
$17B | $2.35 | 5.84% | 39.23% | $110.04 |
|
MRNA
Moderna, Inc.
|
$869.9M | -$2.16 | -34.46% | -5.24% | $36.75 |
|
TIVC
Tivic Health Systems, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
JAGX
Jaguar Health, Inc.
|
$1.13 | $25.50 | $1.4M | -- | $0.00 | 0% | 0.39x |
|
ABT
Abbott Laboratories
|
$124.87 | $144.43 | $217.1B | 15.66x | $0.59 | 1.89% | 4.98x |
|
GOVX
GeoVax Labs, Inc.
|
$0.18 | $9.63 | $5.4M | -- | $0.00 | 0% | 0.79x |
|
MRK
Merck & Co., Inc.
|
$106.45 | $110.04 | $264.2B | 14.08x | $0.85 | 3.08% | 4.20x |
|
MRNA
Moderna, Inc.
|
$32.75 | $36.75 | $12.8B | -- | $0.00 | 0% | 5.68x |
|
TIVC
Tivic Health Systems, Inc.
|
$1.89 | -- | $3.3M | -- | $0.00 | 0% | 3.29x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
JAGX
Jaguar Health, Inc.
|
85.01% | -1.363 | 766.14% | 0.14x |
|
ABT
Abbott Laboratories
|
20.25% | 0.426 | 5.99% | 1.12x |
|
GOVX
GeoVax Labs, Inc.
|
-- | 1.075 | -- | 2.75x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.025 | 20.79% | 1.06x |
|
MRNA
Moderna, Inc.
|
7.29% | 0.934 | 7.28% | 3.30x |
|
TIVC
Tivic Health Systems, Inc.
|
-- | -0.831 | -- | 5.44x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
JAGX
Jaguar Health, Inc.
|
$2M | -$7.2M | -97.4% | -524.57% | -234.77% | -$4.7M |
|
ABT
Abbott Laboratories
|
$5.9B | $2.2B | 22.49% | 29.06% | 19.03% | $2.3B |
|
GOVX
GeoVax Labs, Inc.
|
-$16.8K | -$6.4M | -433.69% | -433.69% | -635.8% | -$6.2M |
|
MRK
Merck & Co., Inc.
|
$13B | $7.5B | 22.23% | 39.63% | 43.43% | $6.8B |
|
MRNA
Moderna, Inc.
|
$757M | -$260M | -27.85% | -30.18% | -25.59% | -$880M |
|
TIVC
Tivic Health Systems, Inc.
|
-$145K | -$2.5M | -212.24% | -212.24% | -1700.69% | -$2M |
Jaguar Health, Inc. vs. Competitors
-
Which has Higher Returns JAGX or ABT?
Abbott Laboratories has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of 14.07%. Jaguar Health, Inc.'s return on equity of -524.57% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital JAGXJaguar Health, Inc.64.58% -$6.28 $36.3M ABTAbbott Laboratories52.05% $0.91 $64.2B -
What do Analysts Say About JAGX or ABT?
Jaguar Health, Inc. has a consensus price target of $25.50, signalling upside risk potential of 2156.64%. On the other hand Abbott Laboratories has an analysts' consensus of $144.43 which suggests that it could grow by 15.97%. Given that Jaguar Health, Inc. has higher upside potential than Abbott Laboratories, analysts believe Jaguar Health, Inc. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings JAGXJaguar Health, Inc.1 0 0 ABTAbbott Laboratories15 7 0 -
Is JAGX or ABT More Risky?
Jaguar Health, Inc. has a beta of -0.122, which suggesting that the stock is 112.17% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.716, suggesting its less volatile than the S&P 500 by 28.412%.
-
Which is a Better Dividend Stock JAGX or ABT?
Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.89% to investors and pays a quarterly dividend of $0.59 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 29.33% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios JAGX or ABT?
Jaguar Health, Inc. quarterly revenues are $3.1M, which are smaller than Abbott Laboratories quarterly revenues of $11.4B. Jaguar Health, Inc.'s net income of -$9.6M is lower than Abbott Laboratories's net income of $1.6B. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 15.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.39x versus 4.98x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAGXJaguar Health, Inc.0.39x -- $3.1M -$9.6M ABTAbbott Laboratories4.98x 15.66x $11.4B $1.6B
-
Which has Higher Returns JAGX or GOVX?
GeoVax Labs, Inc. has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of -630.04%. Jaguar Health, Inc.'s return on equity of -524.57% beat GeoVax Labs, Inc.'s return on equity of -433.69%.
Company Gross Margin Earnings Per Share Invested Capital JAGXJaguar Health, Inc.64.58% -$6.28 $36.3M GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M -
What do Analysts Say About JAGX or GOVX?
Jaguar Health, Inc. has a consensus price target of $25.50, signalling upside risk potential of 2156.64%. On the other hand GeoVax Labs, Inc. has an analysts' consensus of $9.63 which suggests that it could grow by 5197.19%. Given that GeoVax Labs, Inc. has higher upside potential than Jaguar Health, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Jaguar Health, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JAGXJaguar Health, Inc.1 0 0 GOVXGeoVax Labs, Inc.4 0 0 -
Is JAGX or GOVX More Risky?
Jaguar Health, Inc. has a beta of -0.122, which suggesting that the stock is 112.17% less volatile than S&P 500. In comparison GeoVax Labs, Inc. has a beta of 3.638, suggesting its more volatile than the S&P 500 by 263.848%.
-
Which is a Better Dividend Stock JAGX or GOVX?
Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeoVax Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. GeoVax Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAGX or GOVX?
Jaguar Health, Inc. quarterly revenues are $3.1M, which are larger than GeoVax Labs, Inc. quarterly revenues of --. Jaguar Health, Inc.'s net income of -$9.6M is lower than GeoVax Labs, Inc.'s net income of -$6.3M. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while GeoVax Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.39x versus 0.79x for GeoVax Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAGXJaguar Health, Inc.0.39x -- $3.1M -$9.6M GOVXGeoVax Labs, Inc.0.79x -- -- -$6.3M
-
Which has Higher Returns JAGX or MRK?
Merck & Co., Inc. has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of 33.68%. Jaguar Health, Inc.'s return on equity of -524.57% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital JAGXJaguar Health, Inc.64.58% -$6.28 $36.3M MRKMerck & Co., Inc.75.59% $2.32 $93.3B -
What do Analysts Say About JAGX or MRK?
Jaguar Health, Inc. has a consensus price target of $25.50, signalling upside risk potential of 2156.64%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 3.37%. Given that Jaguar Health, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Jaguar Health, Inc. is more attractive than Merck & Co., Inc..
Company Buy Ratings Hold Ratings Sell Ratings JAGXJaguar Health, Inc.1 0 0 MRKMerck & Co., Inc.15 12 0 -
Is JAGX or MRK More Risky?
Jaguar Health, Inc. has a beta of -0.122, which suggesting that the stock is 112.17% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.
-
Which is a Better Dividend Stock JAGX or MRK?
Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.08% to investors and pays a quarterly dividend of $0.85 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios JAGX or MRK?
Jaguar Health, Inc. quarterly revenues are $3.1M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Jaguar Health, Inc.'s net income of -$9.6M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 14.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.39x versus 4.20x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAGXJaguar Health, Inc.0.39x -- $3.1M -$9.6M MRKMerck & Co., Inc.4.20x 14.08x $17.2B $5.8B
-
Which has Higher Returns JAGX or MRNA?
Moderna, Inc. has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of -19.69%. Jaguar Health, Inc.'s return on equity of -524.57% beat Moderna, Inc.'s return on equity of -30.18%.
Company Gross Margin Earnings Per Share Invested Capital JAGXJaguar Health, Inc.64.58% -$6.28 $36.3M MRNAModerna, Inc.74.51% -$0.51 $10.1B -
What do Analysts Say About JAGX or MRNA?
Jaguar Health, Inc. has a consensus price target of $25.50, signalling upside risk potential of 2156.64%. On the other hand Moderna, Inc. has an analysts' consensus of $36.75 which suggests that it could grow by 12.21%. Given that Jaguar Health, Inc. has higher upside potential than Moderna, Inc., analysts believe Jaguar Health, Inc. is more attractive than Moderna, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JAGXJaguar Health, Inc.1 0 0 MRNAModerna, Inc.3 16 1 -
Is JAGX or MRNA More Risky?
Jaguar Health, Inc. has a beta of -0.122, which suggesting that the stock is 112.17% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.
-
Which is a Better Dividend Stock JAGX or MRNA?
Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAGX or MRNA?
Jaguar Health, Inc. quarterly revenues are $3.1M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Jaguar Health, Inc.'s net income of -$9.6M is higher than Moderna, Inc.'s net income of -$200M. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.39x versus 5.68x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAGXJaguar Health, Inc.0.39x -- $3.1M -$9.6M MRNAModerna, Inc.5.68x -- $1B -$200M
-
Which has Higher Returns JAGX or TIVC?
Tivic Health Systems, Inc. has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of -1778.08%. Jaguar Health, Inc.'s return on equity of -524.57% beat Tivic Health Systems, Inc.'s return on equity of -212.24%.
Company Gross Margin Earnings Per Share Invested Capital JAGXJaguar Health, Inc.64.58% -$6.28 $36.3M TIVCTivic Health Systems, Inc.-99.32% -$1.97 $5.6M -
What do Analysts Say About JAGX or TIVC?
Jaguar Health, Inc. has a consensus price target of $25.50, signalling upside risk potential of 2156.64%. On the other hand Tivic Health Systems, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Jaguar Health, Inc. has higher upside potential than Tivic Health Systems, Inc., analysts believe Jaguar Health, Inc. is more attractive than Tivic Health Systems, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JAGXJaguar Health, Inc.1 0 0 TIVCTivic Health Systems, Inc.0 0 0 -
Is JAGX or TIVC More Risky?
Jaguar Health, Inc. has a beta of -0.122, which suggesting that the stock is 112.17% less volatile than S&P 500. In comparison Tivic Health Systems, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock JAGX or TIVC?
Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tivic Health Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. Tivic Health Systems, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAGX or TIVC?
Jaguar Health, Inc. quarterly revenues are $3.1M, which are larger than Tivic Health Systems, Inc. quarterly revenues of $146K. Jaguar Health, Inc.'s net income of -$9.6M is lower than Tivic Health Systems, Inc.'s net income of -$2.6M. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while Tivic Health Systems, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.39x versus 3.29x for Tivic Health Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAGXJaguar Health, Inc.0.39x -- $3.1M -$9.6M TIVCTivic Health Systems, Inc.3.29x -- $146K -$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
